

Application for admission for introduction of new or additional securities of the issuer listed on a non-regulated market of CSE [Emerging Companies Market (E.C.M)]**A. GENERAL INFORMATION****A.1. ISSUER DETAIL**

Issuer Name: IDNA Genomics Public Ltd (the "Company", the "Issuer")

Address: 6 Theotoki Street, 3rd Floor, 1055 Nicosia, Cyprus

Contact person / Nominated Advisor: Prudens Limited

Telephone: +357 22 422240

Email Address: info@idnagenomics.com

A.2. ISSUANCE DETAILS

The issuing company seeks to list the following values:

A. Rights' Issue

B. Warrants

C. Listing additional securities of 10% or more

D. Corporate Bonds

Listing to the Bond Market of the ECM of the CSE 700 convertible, unsecured, non-guaranteed, five (5) year 8,5% bonds, of €1.000 (one thousand EUR) nominal value each, which have already been issued and allotted via private placement to a limited number of persons (fewer than 150 natural or legal persons per member state).

Subsequently the Company may, under the same terms of the Bonds to be listed, issue additional Bonds, bringing the total value of the Bonds to up to €6.000.000 (six million EUR).

The Bonds to be listed in connection hereto are not subject to any offering of securities laws of Cyprus or any other state. They are exempt from the EU Prospectus Regulation and the Prospectus Law, as the Bonds are offered through a private placement to a limited number of persons, i.e., less than 150 natural or legal persons per member state, and as such, the publication of a Prospectus is not required.

The private placement of the Bonds was carried out primarily in EU and was addressed only to persons who lawfully accepted it. Specifically, and in compliance with relevant securities laws of the following countries, this private placement was not addressed in any way or form (written or otherwise), directly or indirectly, to or within the United States, Canada, Australia, South Africa or Japan or any other country ("the Excluded Territories"), in which according to its laws, the conduct of this private placement or the mailing / distribution of this document was illegal or violated any applicable law, rule or regulation. For this reason, it is prohibited to transmit, distribute, post or otherwise promote copies of this document or any promotional and related to this private placement document or other material by any person to or from the Excluded Countries and persons from the Excluded Territories to buy securities.

The initial private placement for the First Tranche took place between the 23rd of January 2023 until the 27th of February 2023. The private placement for the issuance of Further Issues of Bonds continuous and will end on 12/12/23 or when the maximum number of Bonds to be issued is reached, whichever occurs first.

A.3. CONDITIONS OF ISSUE – CORPORATE BONDS

• **Size of issue, nominal value and split**

<i>Characteristics of Bond</i>	:	Convertible, unsecured, non-guaranteed, 5 year 8,5% bonds of nominal value and issue price €1.000 (one thousand EUR) each.
<i>First Tranche</i>	:	€700.000, divided into 700 Bonds.
<i>Initial Issue Date</i>	:	28 th February 2023
<i>Maturity Date</i>	:	28 th February 2028
<i>Interest</i>	:	8,5% per annum
<i>Interest payment Dates</i>	:	Annual anniversary of the Initial Issue Date of the Bonds i.e., the 28 th of February of each calendar year throughout the lifetime of the Bond.
<i>Future Issues of Bonds</i>	:	The Company, subsequently to the First Tranche, may issue Additional Tranches under the same terms and the same ISIN until 28 th of December 2023, bringing the total value of the Bonds to up to €6.000.000 (six million EUR).

If Additional Tranches are issued, the Company will take the necessary steps for the listing of those Bonds on the ECM of the CSE.

• **Registration and transfer**

Pursuant to Clause 21 of the Trust Deed, prior to Listing the Company shall keep a Register at its registered office or at such other place as the Company may decide, as per the relevant provisions of the Companies Act, Cap. 113. Any change of name or address of any Bondholder shall immediately be notified to the Company and, on receipt, the Register held by the Company shall be altered accordingly. Following the Listing, the Register held by the Company shall become inactive and be handed to the CSD Registry and information on the Bondholders shall be held at the CSD Registry, in accordance with the rules, procedures and practices of the CSE.

Additionally, pursuant to Condition 2 of Schedule 1 of the Trust Deed:

- The Bond will be issued to a limited number of persons (fewer than 150 persons) through a private placement at the full discretion of the Board of Directors.
- The minimum investment is €50.000. It is up to the discretion of the Board of Directors to accept applications of amounts below €50.000.
- The Bond is issued to the Bondholders at absolute ownership, enjoyment and possession, and free from any third party right. The Company shall recognize the Bondholder of any Bond as the absolute owner of them and shall not (except as provided by statute or as ordered by a court of competent jurisdiction) be bound to take notice of any trust (whether express, implied or constructive) to which any Bond may be subject.
- The Bonds will be issued in a dematerialized form with their listing to the Bonds Market of the ECM of the CSE. The Bonds are freely transferable. Any transfer will take place by transferring the Bonds through a trade via the market to any third, natural or legal person, without the need for the consent of the Company.

The Bonds of the First Tranche have been issued in full on 28th February 2023. The proof of ownership of each Bondholder is the letter of allotment of the Bonds. The title of the Bonds has been transferred to the Bondholders and no rights are owned by any third parties.

Additional Tranches may be issued before and not later than 28th December 2023, bringing the total value of the Bonds to up to €6.000.000 (six million EUR).

• **Subordination**

Pursuant to Condition 3 of Schedule 1 of the Trust Deed the Bonds constitute direct, unsecured and subordinated securities of the Company and rank *pari passu* without any preference among themselves.

The rights and claims of the Bondholders:

- are subordinated to the claims of the creditors of the Company, who are:
 - (a) Creditors with general or special priorities.

- (b) Subordinated creditors, except those creditors whose claims rank or are expressed to rank pari passu with the claims of the Bondholders of this issue.
 - rank pari passu with the claims of the creditors that it is agreed that they rank pari passu with the claims of the Bondholders of this issue, except in relation to the ordinary shareholders.
 - have priority over the shareholders of the Company.

Additionally, according to Clause 3 of the Trust Deed, the Company has the power, without the consent of the Bondholders, to create and issue further bonds ranking pari passu or junior in point of security and/or subordination with the Bond and either (a) carrying the same rights in all respects as the Bond and forming one class with the Bond, or (b) having such terms as the Company may determine at the time of their issue.

- **Claims in case of dissolution**

Pursuant to Condition 8.1(d) of Schedule 1 of the Trust Deed, the Bonds then in issue shall be immediately redeemed at the principal amount, together with interest on the Bonds outstanding, if, among others, *“an order is made, or an effective resolution is passed, for the winding-up, liquidation, administration or dissolution of the Company (except for the purpose of reorganisation or amalgamation of the Company or any of its subsidiaries)”*.

Pursuant to Condition 11 of Schedule 1 of the Trust Deed *“if any order is made by any competent court or resolution passed for the winding-up or dissolution of the Company, save for the purposes of reorganisation on terms previously approved in writing by the Trustee or by an Extraordinary Resolution,”*:

- the Trustee at its discretion may give notice in writing to the Company that the Bond is, and the Bond shall thereupon immediately become, due and repayable at the principal amount together with accrued interest plus Default Interest on an annual compounding basis as provided in the Trust Deed; or
- if the Trustee has been so requested in writing by the Bondholders of at least 75 per cent in principal amount of the Bond then outstanding or if so directed by an Extraordinary Resolution (subject in each case to being secured and/or indemnified to its satisfaction), the Trustee shall, give notice in writing to the Company that the Bond is, and the Bond shall thereupon immediately become, due and repayable at their principal amount together with accrued interest plus Default Interest on an annual compounding basis as provided in the Trust Deed.

- **Deferred payment of interest**

Not applicable.

- **Interest payment (interest rate, interest payment date, the basis for calculating interest)**

Pursuant to Condition 5 of Schedule 1 of the Trust Deed, the Bond will bear interest from (and including) the Initial Issue Date at an annual rate of 8.5%, payable in arrears on each Interest Payment Date in respect of the period from and including the immediately preceding Interest Payment Date of the Bond until, but excluding, the current Interest Payment Date. Interest shall be calculated on the basis of the actual number of days elapsed in the relevant period and a 365day year. The Interest Payments Dates of the Bond are 28th of February of each calendar year throughout the lifetime of the Bond.

In case of default in the payment of interest due as per the previous paragraph, Default Interest will apply in respect of the amount of interest due and payable after deducting the amount (if any) that was paid on each Interest Payment Date.

Each Bond will cease to bear interest from (and including) the Conversion Date or its due date for redemption (see section below ‘Exchange of values of subordinate capital, change the terms, redemption’), unless payment of the principal in respect of the Bond is improperly withheld or refused or unless default is otherwise made in respect of payment, in which event interest shall continue to accrue.

When interest is required to be calculated in respect of a period that ends prior to an Interest Payment Date, it shall be calculated on the basis of (a) the actual number of days in the period from (and including) the date from which interest begins to accrue to (but excluding) the date on which it falls due divided by (b) 365 days, and multiplying this fraction by the rate of interest and the relevant principal amount of the Bond.

Pursuant to Condition 6 of Schedule 1 of the Trust Deed, payment of interest in respect of the Bond will be made up to ten (10) business days after the Interest Payment Date to the relevant Bondholder appearing on the Register on the Interest Payment Date. The Record Date for the eligible Bondholders will be the business day preceding the Interest Payment Date.

It is also noted that pursuant to the relevant applicable CSD provisions, the Ex-Interest Date will be the business day preceding the Record Date and the Cum-Interest Date will be the business day preceding the Ex-interest Date.

Payment will take place by (a) direct deposit of the Company to the account of each Bondholder, or (b) a cheque issued in the Bondholder's name, or (c) a bank transfer to the CSD operator, indicated in the CSD, for the purposes of further crediting the Bondholder's account, as it shall be stated in writing to the Company. The Company is obliged to provide to the Trustee the proofs of payment of the interest amounts, otherwise, the payment is rendered overdue without notice will be charged with Default Interest from the first date of delay of payment.

- **Alternative Payment interest mechanism**

Not applicable.

- **Exchange of values of subordinate capital, change the terms, redemption**

- Change of terms

Pursuant to Clause 25 of the Trust Deed is a legally binding document and it is possible to modify or amend it with the consent of all parties to it and with the approval of an Extraordinary Resolution. Additionally, according to Condition 13 of Schedule 1 of the Trust Deed contains provisions for convening meetings of Bondholders to consider matters affecting their interests, including the sanctioning by Extraordinary Resolution of a modification of any of the conditions or any provisions of the Trust Deed. Any Extraordinary Resolution duly passed shall be binding on the Bondholders (whether or not they were present at the meeting at which such resolution was passed).

Following the successful Listing on the ECM of the CSE, the Company will need to receive a special permit from CSE Council pursuant to section 5.2.11 of the CSE Regulatory Decisions, granting it the right to amend the terms of the Bond, before any such Extraordinary Resolution can be put into effect.

- Exchange of values/ Conversion of Bond

Pursuant to Condition 7 of Schedule 1 of the Trust Deed, the Bondholders have the right to convert all or part of their Bonds into Shares on a Conversion Date (the 3rd 4th and 5th anniversary of the Initial Issue Date of the Bond, i.e., the 28th of February of 2026, 2027 and 2028), by giving to the Company 21 business days' notice in writing in a form that will be provided by the Company at least two months before the first applicable Conversion Date, i.e., 28th February 2026. The Conversion Price equals to €24/ Share and the conversion ratio will be determined by dividing the nominal value of the Bond (i.e., €1.000) by the Conversion Price of the Bond per Share (i.e., €24). Calculation for such number of Shares shall be rounded up (if 0,5 or over) or down to the nearest whole Share.

For example, if a Bondholder chooses to convert 100 Bonds to new Shares, considering the Conversion Price of €24,00 per Share and the nominal value of the Bond of €1.000 each, the Company will issue 4.167 Shares (round up from 4.166,67) on the Conversion Date applicable.

The Conversion Price will be adjusted in the event that there are corporate actions, which have an effect on the price of the Share, such as consolidation, reclassification or subdivision of the Shares, capital distributions, rights issues or other adjustments which affect the Shares.

The Company will give sufficient notice to the Bondholders and make all relevant announcements to the CSE, regarding upcoming Conversion Dates and any adjustments on the Conversion Price.

Further and pursuant to Condition 8.1 (e) of Schedule 1 of the Trust Deed, notwithstanding any other term(s) relating to the Conversion of the Bonds, where a person gains control of the Company, any Bonds may be converted in their entirety (or any part thereof) on the terms of the Trust Deed within six (6) months of the time when the person making the offer has obtained control of the Company and any condition subject to which the offer has been made has been satisfied. A person shall be deemed to have obtained control of the Company as a result of making a general offer to acquire the whole or a majority share of the issued share capital of the Company, which subsequently results in the person making the offer having control of the Company.

Any Bond converted into Shares shall be cancelled and may not be issued or resold. Shares arising on conversion of the Bonds shall be issued and allotted by the Company on the Conversion Date of the Bond. Each new Share arising on conversion shall be issued and allotted at such premium to reflect the difference between the nominal value of the Share and the nominal value of Bonds converted into new Shares on the Conversion Date of the Bond. The new Shares arising on conversion of the Bond shall be credited as fully paid and rank pari passu with the Shares of the same class in issue on the Conversion Date of the Bond and shall carry the right to receive all dividends and other distributions declared after the Conversion Date of the Bond. The Shareholders at the EGM of 28th December 2022 waived any and all pre-emption rights that they have or may have in connection with a possible issue of new Shares from the conversion of Bonds. Taking into consideration, that the Company may issue up to 6.000 Bonds, the maximum number of Shares that could be issued resulting from this Bond amounts to 250.000 Shares, bearing in mind the Conversion Price is not adjusted.

– **Redemption of Bonds**

Unless previously converted, redeemed or purchased and cancelled, the Bond will be redeemed by the Company at par on the Maturity Date of the Bond, i.e., 28th February 2028.

In accordance with Condition 8.3 of Schedule 1 of the Trust Deed, the Company may purchase all or part, of the outstanding Bond at any time, by providing a 15 days' written notice and announcement to the Bondholders prior to the date of the payment.

Any Bond purchased by the Company shall be cancelled and may not be issued or resold.

• **Not prompt payment**

Pursuant to Condition 11.1.B (a) of Schedule 1 of the Trust Deed, a default in the payment of any principal or interest due in respect of the Bond, or any of them, which continues for a period of seven (7) days in the case of principal and fourteen (14) days in the case of interest, shall be deemed an event of default.

• **Allocation of Bonds to non-permanent residents of Cyprus**

The Bonds to be listed were offered through a private placement to a limited number of persons, i.e., less than 150 natural or legal persons per member state. Persons whose permanent residents is outside of Cyprus are permitted to purchase and hold the Bonds, pursuant to the applicable laws in force at the time. Prospective investors should consult their own tax advisors regarding the Cypriot or other tax related matters arising from the acquisition, holding and disposal of the Bonds, taking into consideration their own personal situation and particular circumstance.

• **Trust document**

The Company has arranged for the appointment of a competent person as a Trustee, Crowdbase Ltd, for the protection of the interests and rights of the Bondholders. Crowdbase Ltd, is a regulated Cyprus Investment Firm (CIF) under the Cyprus Securities and Exchange Commission (license number 410/22) and is independent from the Company.

A legally binding document, the Trust Deed dated 18th January 2023, has been drawn and concluded between the Company and the Trustee, providing that it is possible to amend it with the consent of the beneficiaries of 75% of the outstanding Bond.

The Trust Deed has been submitted to the CSE and is available at the registered offices of the Company and the Trustee.

• **Notices and Announcements**

– **Notices**

Pursuant to Clause 24 of the Trust Deed, notices to be given to Bondholders regarding the Bond will be deemed to be validly given if sent by post to the Bondholders at their addresses entered in the Register or by means of electronic communication if a Bondholder has provided electronic communication details. Any such notices will be deemed to have been given on the date falling five days after the date of dispatch of such letters or on the same day in the case of electronic transmission. In the case of joint Bondholders, a notice given to the holder whose name stands first in the Register in respect of such Bond shall be sufficient notice to all the joint holders of such Bond.

Notices to be given by any Bondholder shall be in writing and will be deemed to be validly given if received at the then-current registered office of the Company, on the date they shall be received.

– **Announcements**

The Company shall also ensure that notices are duly published in a manner which complies with the rules of any exchange on which the Bond is for the time being listed or other relevant authority regulating the Bond. Accordingly, the Company will make announcements and/or publications as provided for by the legislation and the CSE Regulatory Decision.

• **Additional Issues**

Pursuant to Condition 1 of Schedule 1 of the Trust Deed, the Bond may be issued in tranches; the first tranche being, before and not later than 31st March 2023 and thereafter there may be further tranches issued before and not later than 28th December 2023. Each tranche will be issued in a principal amount comprising part of the total amount of the Bond.

The Company has issued 700 Bonds. The Company, subsequently to the First Tranche, may proceed with Additional Tranches under the same terms and the same ISIN until 28th of December 2023, bringing the total value of the Bonds to up to €6.000.000 (six million EUR).

In case of any Additional Tranches are issued, the Company will take the necessary steps for the listing of those Bonds on the ECM of the CSE.

Pursuant to Condition 15 of Schedule 1 of the Trust Deed the Company has the power, without the consent of the Bondholders, to create and issue other bonds ranking pari passu or junior in point of security and/or subordination with the Bond and either (a) carrying the same rights in all respects as the Bond and forming one class with the Bond, or (b) having such terms as the Company may determine at the time of their issue.

• **Listing to CSE trading / transfer of securities**

Pursuant to Condition 2(d) of Schedule 1 of the Trust Deed, the Bonds will be issued in a dematerialized form with their listing to the Bonds Market of the ECM of the CSE. The Bonds are freely transferable. Any transfer will take place by transferring the Bonds through a trade via the Bonds Market of the ECM of the CSE to any third, natural or legal person, without the need for the consent of the Company. The trading currency of the Bond will be Euros (€) and the trading unit will be one (1) Bond.

• **Trading Method – clean price or dirty price**

Upon the admission to trading on the ECM, the Bonds will be trading at dirty price.

B. BOARD OF DIRECTORS

Board of Directors	
Name	Position
Mr Fotios Sakellarides	Executive Director
Mr Antonios Nikolaou	Executive Director

C. DEVELOPMENT OF THE ISSUER

- Summarize the development of the issuer since the last publication of the Prospectus / Admission Document to date and make a reference to major events (eg takeovers, etc.).

iDNA Genomics Public Ltd was incorporated in Cyprus on 16th November 2020 pursuant to the Companies Law, Cap. 113, as a public company limited by shares with registration number HE415277 and the name iDNA Genomics Public Ltd.

On the 30th of September 2021, the Company acquired iDNA Genomics IKE, an emerging, privately held personal genomics and biotechnology company registered in Greece with General Electronic Commercial Registry number 152515201000 and headquarters in Kifissia, Athens. Through this acquisition, the Company also indirectly acquired the subsidiary of iDNA Genomics IKE, iDNA Laboratories IKE, a privately held diagnostic centre registered in Greece with General Electronic Commercial Registry number 157439801000.

The Group's goal is to become a world class player in the booming market of DNA testing & analysis and be recognized as the most innovative and trusted "personalized genetic knowledge" provider for a healthy life management.

On the 17th of December 2021 the Company was successfully listed on the ECM of the CSE and its Shares are traded under the financial instrument code IDNA and ISIN: CY0109800710.


On the 30th of December 2022, the Company acquired 5% of Theracell Advanced Biotechnology S.A., a leading biotechnology company based in Greece, specializing in the development and commercialization of a diverse pipeline of CGT (Cell and Gene Therapy) products. This investment falls within the Company's strategic objectives and its estimated value is €3,8million.







Since its incorporation, the Group has hit certain specific milestones and achievements, such as achieving the listing of its Shares on the ECM of the CSE in December 2021, as well as the development and launch of its PEARL platform. Summarized highlights include:

2019-2020: <i>Development & Launch</i>	<ul style="list-style-type: none"> • Incorporation of iDNA Genomics IKE and iDNA Genomics Public Ltd. • Development and launch of CNS PGx & 4 Wellness tests. • Launching of e-shop.
2021: <i>Operational Build Up</i>	<ul style="list-style-type: none"> • Incorporation of iDNA Laboratories IKE, as a subsidiary of iDNA Genomics IKE. • The Company acquires iDNA Genomics IKE. • Listing of the Company on the CSE, with market capitalization of €62,4 million (based on valuations). • Launching iDNA online. • ISO certifications and CE IVD Certification for CNS PGx.
2022: <i>Developing in Greece & Preparation for international Markets</i>	<ul style="list-style-type: none"> • Launch of CVD Predisposition test & Nutritional guide as CE IVD Certified Tests. • Technical files preparation & PGx CNS Reimbursed. • PEARL platform ready. • The Company acquired 5% of Theracell Advanced Biotechnology S.A.

C.1. CURRENT PRODUCT PORTFOLIO

The Group's focus is on developing and providing Genetic Testing Analysis in both sectors of Medical Genomics and DTC Genomics. The Group's current product portfolio is as follows:

Medical Genomics Product Line	
<p>iDNA CNS PGx: a pharmacogenetic Analysis for CNS drugs. <i>It is the only CE IVD PGx test, already used from more than 3000 Greek patients and currently filed to EOPYY for reimbursement on Depression Disorder.</i></p>	

<p>iDNA Cardio Health: for Cardiovascular predispositions. <i>It is the only CE IVD test, which evaluates individualized risk of developing 5 cardiovascular diseases, using the proprietary Polygenic Risk Score (PRS) algorithm and the Adjusted PRS score.</i></p>	
DTC Genomics Product Line	
<p>iDNA NutriGenetix Kit: Nutrigenetics <i>It helps people compare their genetic analysis vs. their current nutritional status and provides tailored diet to meet individual weight management goals. It is the only CE IVD Nutrigenetics test.</i></p>	
<p>iDNA Nutrition DNA Test <i>It helps people to personalize their diet, manage their weight, and discover their nutritional sensitivities and detoxification capacity.</i></p>	
<p>iDNA Exercise DNA Test <i>It helps people to build their own exercise program and discover their athletic profile and predisposition to injuries.</i></p>	
<p>iDNA Vitamins & Minerals DNA Test <i>It helps people to prevent deficiencies in vitamins and minerals by discovering how their body absorbs and processes them from the foods as well as, detoxification capacity & antioxidant needs.</i></p>	
<p>iDNA 3 in 1 <i>It Includes 40 categories of Nutrition, Exercise and Vitamins, providing the most comprehensive personalized report analysis</i></p>	

C.2. AWARDS

In December 2022, the Group was honored by Elevate Greece, a Governmental initiative to support Greek Ecosystem of start-ups that demonstrate high INNOVATION & EXCELLENCE in business. The Group was subsequently awarded with the “Women’s Entrepreneurship Award 2022”.

This distinction provides the Group with significant benefits related to the following:

- Networking opportunities within the ecosystem but also at international level;
- Cash prize;
- State support measures with special state aid programs; and
- Company image & awareness at international level.



- *Indicate any litigation/ juridical difference, arbitration or interruption of activities that it has or had, in the recent past, significant effects on the financial position of the issuer.*

The Company has had no litigation/ juridical difference, arbitration or interruption of activities that has or has had, in the recent past, significant effects on its financial position.

D. DEVELOPMENT OF THE SHARE CAPITAL AND THE ISSUE OF THE BONDS

- Refer to the amount of the issued share capital, number and categories of shares that represent as well as to their main characteristics

Authorized Share Capital: : €100.000 (divided into 10.000.000 ordinary shares of nominal value €0,01 each)
 Issued Share Capital: : €27.603 (divided into 2.760.333 ordinary shares of nominal value €0,01 each)

The Company was incorporated with an issued share capital of €26.000 divided into 2.600.000 ordinary shares of nominal value €0,01 each.

On the 17th of December 2021 the Company was successfully listed on the ECM of the CSE and its Shares are traded under the financial instrument code IDNA and ISIN: CY0109800710.

Following a decision of an EGM dated 29th December 2022, 160.333 new Shares were issued and allotted on 30th December 2022 to Mr Fotis Sakellarides, in exchange for 5% of the issued share capital of Theracell Advanced Biotechnology S.A. (for the estimated value of €3.848.004). The 160.333 new Shares were successfully admitted to trading on the 15th of February 2023 and were incorporated into the listed share capital of the Company.

- Refer to resolutions, authorizations and approvals under which the Bond was issued or will be issued

Further to the above, on the same EGM on the 29th December 2022, the following resolutions were also examined and approved:

- The Board was authorized to issue and allot up to 6.000 convertible, unsecured, non-guaranteed, 5- year 8,5% bonds of nominal value €1.000 each;
- The issued Bonds to be listed on the Bond Market of the ECM of the CSE;
- The Shareholders waived any and all pre-emption rights that they have or may have in connection with a possible issue of new Shares from the conversion of Bonds; and
- The Board was authorized to duly proceed with all actions and measures necessary for the implementation and fulfilment of the above resolutions.

On the 28th of February 2023, the Board of Directors decided, at its absolute discretion, the issuance and allotment of 700 Bonds as below:

- 500 Bonds to Mr Ioannis Papaevaggelou
- 200 Bonds to Ms Ileana Vozemberg - Vretou

E. MAIN SHAREHOLDERS

- As of the date of this Admission Document

	Shareholder	Direct	Indirect	Total	
				Shares	%
A.	Members of the Board of Directors Fotios Sakellarides	410.333	1.022.200	1.432.533	51,9%
B.	Majors Shareholders (5% and over) Stamatios Molaris**	420.710	553.910	974.620	35,3%
C.	Free float to the public	353.180	0	353.180	12,79%
	Totals	1.184.223	1.576.110	2.760.333	100,0%

- * The indirect holdings of Mr Fotios Sakellarides are comprised of the Shares which are held by his sons, Mr Emmanuel Sakellarides (632.200 Shares) and Nikolaos Sakellarides (390.000 Shares).
- ** The indirect holdings of Mr Stamatios Molaris are comprised of the Shares which are held by his wife Ms Fuzeyyia Yener Molaris (118.520 Shares), his son Mr Vasileios Alexandros Molaris (428.800 Shares), and the companies controlled by him Don Quixote Consultants Company (3.300 Shares) and Tolstoy Trading Co (3.290 Shares).

F. FUNDRAISING

- *Please specify the value of the fund raised and how the capital raised is intended to be used in connection with the strategic plan of the issuing company.*

The Company has raised a total of €700.000 via the First Tranche and may raise up to €6.000.000 via Additional Tranches. The Group plans to use the funds raised via the issue of the Bonds to execute the next stage of its business plan, specifically its Marketing and Expansion Plan, taking advantage of the opportunities in available markets, i.e., research and development, expansion, and approximately €500.000 for listing on NASDAQ Stock Exchange.

2023: <i>First international launches</i>	<ul style="list-style-type: none"> • Continued sales growth in Greece. • Secure country expansion and strategy with respective partners: <ul style="list-style-type: none"> – Germany, MEA • Research & Preparation for US entry. • Listing on NASDAQ Stock Exchange. • Preparation for next market expansions.
2024: <i>Further growth & development of markets</i>	<ul style="list-style-type: none"> • Sales growth. • Secure country entrance and strategy with the respective partners: <ul style="list-style-type: none"> – UK, Italy, Spain, France, rest EU, Asia
2025 onwards: <i>Continued expansion and new opportunities</i>	<ul style="list-style-type: none"> • Continued sales growth and penetration in all markets. • Continued research and preparation for: <ul style="list-style-type: none"> – New brands and products, and – New markets.

G. FINANCIAL INFORMATION

- *Refer to whether in the last audit report the company's auditors expressed any Disagreement, Limitation of scope, Adverse opinion, Disclaimer of opinion or Emphasis of matters (Qualification on the auditors' report) If YES, please illustrate.*

The auditors of the Company did not express any Disagreement, Limitation of scope, Adverse opinion, Disclaimer of opinion or Emphasis of matters (Qualification) on the auditors' report in the Audited Consolidated Financial Statements of the Company for the year ended 31st December 2022.

H. OTHER INFORMATION ON THE ISSUER'S SECURITIES

- **Free transfer**

(Is there any restriction on the transfer of new securities by any shareholder of the company to another? Are there any agreements that may restrict the free transfer of shares? If yes, please attach copies to the CSE.)

- There are no restrictions on the transfer of any securities of the Company.
- There are no agreements that may restrict the free transfer of the securities of the Company.

- **Special rights**

(Are there any significant agreements with the company's board of directors or major shareholders and related parties to these people? If yes, then attach the agreements)

- The Company has not granted any special rights to any holder of securities of the Company.
- There are no significant agreements with the Company's Directors or major shareholders of the Company or related parties to these people with respect to any special rights on securities.
- The Company is not bound and will not bind itself against anyone in a manner which is incompatible with the best interests of its security holders.
- The Company ensures equal treatment of all of its security holders, in relation to all rights and obligations that are allotted to them through the ownership of those securities.

- **Special Resolution to Issue Shares**

(In case of securities, the issuer must ensure that any future issue will be offered first to existing shareholders in proportion to the percentage each one holds in the capital of the issuer, unless with a special resolution of the shareholders decide otherwise.)

- At the EGM dated 29th December 2022, the Shareholders waived any and all pre-emption rights that they have or may have in connection with a possible issue of new Shares from the conversion of Bonds.
- Any other future issues of Shares will be offered first to existing Shareholders in proportion to the percentage each one holds in the capital of the Company, unless the Shareholders with a special resolution decide otherwise.

- **Fully paid titles**

- The Bonds proposed for the Listing are fully paid.

I. OTHER INFORMATION ABOUT THE ISSUER

- **Market Capitalization**

- The market capitalization of the Bond to be listed amounts to €700.000.
- The equity of the Company as of the date of this Admission Document amounts to € 74.528.991
- Number of Bonds: 700
- Exercise-Price / Issue Price: €1.000 each (nominal value)
- Average Trading Price: Not applicable

- **Code of Corporate Governance**

(Statement of the company whether applies the Corporate Governance Code)

- The Company does not apply the CSE Corporate Governance Code

- **Central Depository and Registry**

The publisher is ready and able to deliver the Register in the Central Depository and Registry and to meet any requirement at the start or during the follow up of the registers or records of the registered holders of securities


- Yes. The Company is willing and able to deliver its Register to the CSD and to fulfil any obligation with regards the delivery of the Register or the continued maintenance of the Register.

(The CSE Council has the power to request additional information or details.)


Mr Fotis Sakellarides, Executive Director of the iDNA Genomics Public Ltd, declares that "awareness of the consequences of the Act, that the answers to all above questions are true.

Signature

IDNA GENOMICS PUBLIC LTD



Director
iDNA Genomics Public Ltd



Nominated Advisor
Prudens Limited **PRUDENS LTD .**

J. ADDITIONAL SPECIAL INFORMATION FOR LISTING OF SECURITIES TO THE EMERGING COMPANIES BOND MARKET

1. Listing of shares from the conversion or exchange of bonds

(If the bonds are converted or exchanged into shares or rights to acquire shares, the shares in which they are reported should be listed on the Stock Exchange or other non-regulated market)

- The Bond is convertible and may be converted into Shares on the Conversion Dates.
- The Shares of the Company are listed on the ECM of the CSE and trade under the financial instrument code IDNA and ISIN: CY0109800710.

2. Appointment of trustee

The issuing company has taken care to appoint a suitable person as trustee to protect the interests and rights of the holders of the bonds;

- The Company has appointed Crowdbase Ltd as the Trustee of the Bond.
- Crowdbase Ltd, a company registered in the Republic of Cyprus with registration number HE414264, regulated under the Cyprus Securities and Exchange Commission (Cyprus Investment Firm license number 410/22) and independent of the Company.

3. Document Binding

The issuing company has produced and published a binding legal document * which provides that it may be amended only with the consent of holders of 75% of total bonds and which are regulated or listed:

- | | |
|--|-------------------------------------|
| 1. The rights and obligations of the issuer against beneficiaries or their representatives or trustee beneficiaries | <input checked="" type="checkbox"/> |
| 2. The relationship of beneficiary rights to rights holders of other bonds and debt securities of the same issuer or another issuer from which the issuer or funds are determined. | <input checked="" type="checkbox"/> |
| 3. The sinking fund, the repayment process, or other provisions relating to the amortization of debt | <input checked="" type="checkbox"/> |
| 4. In the case of bonds whose repayment or partial repayment is guaranteed by a third person copies of the order or document to which such guarantee is offer | <input type="checkbox"/> |
| 5. The name or names of dealers or trustee for representation and protection of the interests of beneficiaries terms replacement and responsibilities thereof | <input checked="" type="checkbox"/> |

4. Trading Price

Whether the securities will be traded under conditions of clean price or dirty price

- Upon their admission to trading on the ECM, the Bonds will trade at dirty price.

**In cases where the binding document has not been previously submitted to the CSE*

K. Appendix 1 - Definitions

€, Euros	: Currency in Euros.
iDNA Genomics Public Ltd., iDNA, the Company, the Issuer	: IDNA Genomics Public Ltd, incorporated in Cyprus on 16 November 2020 pursuant to the Companies Law, Cap. 113, as a public company limited by shares and with registration number HE415277.
Additional Tranches	: The issuance by the Company of up to 5.300 Bonds, under the same terms and the same ISIN, bringing the total value of the Bonds to up to €6.000.000 (six million EUR).
Admission Document	: The current application for admission of the Company (Annex 22) dated 5 th May 2023, which was prepared pursuant to the CSE Regulatory Decision.
Board of Directors, the Board	: The Board of Directors of the Company.
Bond	: Up to €6.000.000 of the convertible, unsecured, non-guaranteed 8,5%, five (5) year bond of the Company of nominal value €1.000 (one thousand EUR) each, issued pursuant to the Trust Deed. The Bond will not be secured or guaranteed by the Issuer or any other third party. The Bond carries an annual interest of 8,5%, paid out annually on the Interest Payment Date. The Bond matures on 28/2/2028.
Bondholder	: The holders of the Bond.
Conversion Dates	: The 3 rd 4 th and 5 th anniversary of the Initial Issue Date of the Bond, i.e., 28/2 of 2026, 2027 and 2028.
Conversion Price	: The price at which the Bond may be converted to Shares and equals to €24,00 per Share [rounding up (if 0,5 or over) or down to the nearest whole Share]. The Conversion Price will be subject to adjustments in the event that there are corporate actions, which have an effect on the price of the Shares.
Corporate Governance Code	: The Corporate Governance Code of the CSE.
CSD	: The Central Securities Depository and Central Registry operated by the CSE.
CSE	: The Cyprus Stock Exchange.
CSE Regulatory Decisions	: The Regulatory Decisions of the Council of the Cyprus Stock Exchange on the Stock Exchange Markets (RAA 379/2014, as amended).
Default Interest	: The annual default interest rate of 1%, payable in accordance with the relevant provisions of the Conditions of Schedule 1 of the Trust Deed, i.e., the additional 1% interest rate, payable by the Company to the Bondholders if any event of default occurs and the Company fails to fulfil certain obligations on time, such as the payment of the interest or the redemption of the Bond.
Directors	: The members of the Board of Directors of the Company.
DNA	: A common abbreviation of 'deoxyribonucleic acid' and is generally used to refer to an individual's genetic makeup.
DTC Genomics	: Direct-to-consumer (DTC) genomics is the direct marketing and selling of genomic tests to the consumer and provide the consumer with access to their genetic information without the involvement of a health care professional.
ECM	: The bond market of the Emerging Companies Market (non-regulated Multilateral Trading Facility) of the Cyprus Stock Exchange.
EGM	: An Extraordinary General Meeting of the Shareholders of the Company.
EOPYY	: The National Organization for the Provision of Health Services of Greece (EOPYY).
EU Prospectus Regulation	: The Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the

	public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC.
<i>Extraordinary Resolution</i>	: A resolution by the Bondholders of not less than 75 per cent of the nominal amount of the Bond for the time being outstanding.
<i>First Tranche</i>	: The initial amount of Bonds issued by the Company on the 28 th of February 2023; being 700 Bonds.
<i>Group</i>	: The Company and its Subsidiaries.
<i>Initial Issue Date</i>	: The date of issue of the First Tranche being 28/2/2023.
<i>Interest Payment Date</i>	: 28/2 (28 th of February) of each calendar year throughout the lifetime of the Bond.
<i>Listing</i>	: The listing on the ECM of the First Tranche of Bonds, that were allotted via a private placement to a limited number of persons.
<i>Listing Price</i>	: The price at which Bonds will be listed and will commence trading on the ECM, which is the nominal value of the Bond, €1.000 (one thousand EUR) each.
<i>Maturity Date</i>	: The date of repayment of the Bond i.e., 28/2/2028, 5 years after the Initial Issue Date.
<i>Medical Genomics</i>	: Medical genomics is the application and integration of genomic and other data to better understand the genetic bases of drug response and disease. Medical genomics are marketed through health care professionals, who receive the consumer's/patient's genetic information, and then liaise with the regarding their genetic test results.
<i>Nominated Advisor, Prudens</i>	: Prudens Limited, the nominating advisor of the Company, which is an administrative service provider (ASP) being regulated by the Cyprus Bar Association, incorporated in Cyprus pursuant to the Companies Law, Cap. 113 as a private company limited by shares.
<i>PEARL</i>	: The Group's novel artificial intelligence platform.
<i>Prospectus Law</i>	: The Public Offer and Prospectus Law, L.114(I)/2005, as amended and to the extent that it is applicable after the EU Prospectus Regulation came into force.
<i>Register</i>	: The register of the Bondholders.
<i>Shares</i>	: The ordinary shares of the Company of nominal value €0,01 each.
<i>Shareholders</i>	: The registered owners of Shares.
<i>Subsidiaries</i>	: The subsidiary companies of the Company, which at the time of this Admission Document are the following: <ul style="list-style-type: none"> • iDNA Genomics IKE, and • iDNA Laboratories IKE.
<i>Trust Deed</i>	: The trust deed document dated 18 th January 2023 between the Company and the Trustee.
<i>Trustee</i>	: The trustee of the Bond, Crowdbase Ltd, a company registered in the Republic of Cyprus with registration number HE414264 and regulated under the Cyprus Securities and Exchange Commission (Cyprus Investment Firm license number 410/22).